Bausch Health Companies acquires US rights from Eton Pharma to EM 100 , an OTC eyedrop to treat ocular itching.

Bausch Health Companies Inc.and Bausch + Lomb, its wholly owned subsidiary and a leading global eye health company, and Eton Pharmaceuticals, Inc. announced a subsidiary of Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals' EM 100, an investigational eye drop that, if approved, will be the first over-the-counter (OTC) preservative-free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis.

EM 100 has been submitted to the FDA for review. Eton Pharmaceuticals previously reported positive top-line results from a Phase III trial in which EM I00 demonstrated statistically significant superiority to placebo and no adverse events, and demonstrated non-inferiority to a comparator product in the treatment of ocular itching.